For instance, thyroid cancers which had mutations in codons 12 or 13 of KRAS were found to be associated with comparatively lower malignant outcomes (41.7%) as compared to mutations in codon 61 of NRAS (86.8%) and codon 61 of HRAS (95.5%). This evidence concerns the gene KRAS and thyroid cancer.